Some health care CEOs are praising TrumpRx for empowering consumers to compare drug prices

(Credit: Nathan Howard/Getty Images)

• In today’s CEO Daily: Diane Brady reports on CEOs’ reaction to the launch of TrumpRx.
• The big leadership story: The first-ever CEO of the IRS is drawing on his private sector experience.
• The markets: Up globally, with Japanese stocks hitting fresh highs after Prime Minister Sanae Takaichi’s party won a general election landslide.
• Plus: All the news and watercooler chat from Fortune.

Good morning. After months of waiting, the Trump administration last week launched TrumpRx.gov, a direct-to-consumer platform offering 43 brand-name prescription drugs with varying levels of discounts. I’ve been talking to CEOs in all parts of the health care industry, from the drugmakers and insurers to those leading digital health platforms that now compete—and cooperate with—the new government site. “It’s another platform that Americans can use to compare pricing,” said Wendy Barnes, CEO of GoodRx, one of several platform partners with TrumpRx. “At present, I rate it positively from our perspective because it expands our reach and aligns with our mission.”